Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification to the market regarding the Company's issued share capital and voting rights structure as of June 30, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
Material Changes
The filing details the Company's capital structure as of June 30, 2009:
- Total issued share capital: 5,662,588,631 Ordinary shares of 25p each.
- Treasury shares held: 474,194,158 Ordinary shares.
- Total voting rights: 5,188,394,473.
No comparative data for prior periods is included in this specific filing to determine material changes in capital structure.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,188,394,473) to determine notification thresholds under Financial Services Authority rules.
- Confirm the number of shares held in Treasury (474,194,158) which are excluded from voting rights calculations.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.